Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
about
Emerging role of novel biomarkers in the diagnosis of inflammatory bowel diseaseCUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseasesNovel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodiesIntegrity of Narrow Epithelial Tubes in the C. elegans Excretory System Requires a Transient Luminal MatrixEscherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease.The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I).The role of bacteria in the pathogenesis of inflammatory bowel diseaseBacterial protein signals are associated with Crohn's disease.Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer.Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.Pathogenesis of Crohn's disease: Bug or no bug.Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel diseaseCDKAL1-related single nucleotide polymorphisms are associated with insulin resistance in a cross-sectional cohort of Greek children.Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.Microbial Translocation and B Cell Dysfunction in Human Immunodeficiency Virus Disease.A Potential Role of Salmonella Infection in the Onset of Inflammatory Bowel DiseasesMicrobial TLR Agonists and Humoral Immunopathogenesis in HIV Disease.Proteomic analysis of zymogen granules.Serological markers of inflammatory bowel disease.New serological markers in pediatric patients with inflammatory bowel disease.Clinical aspects of indirect immunofluorescence for autoimmune diseases.Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity.Identification of Antibody Against SNRPB, Small Nuclear Ribonucleoprotein-Associated Proteins B and B', as an Autoantibody Marker in Crohn's Disease using an Immunoproteomics Approach.Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases.Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis.Identification of adhesin-receptor interactions driving bacterial translocation through M cells.Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's DiseaseCrohn's disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease.The influence of gluten on clinical and immunological status of common marmosets (Callithrix jacchus).Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.Species-specific and pathotype-specific binding of bacteria to zymogen granule membrane glycoprotein 2 (GP2).Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.
P2860
Q26768273-2CA3BD41-E5F5-465F-858D-238043418847Q26999045-62A2C0A9-BB1E-4378-A4F3-D5003B35643AQ27000411-84A4643C-ED8C-494B-B572-82775F9C80DEQ27308141-C72A68DC-A067-484A-93BC-6A9DF6FB44AAQ33958858-968607E2-0048-46AB-BF86-E77899875CF8Q34156890-29810268-D888-405D-B01E-E88E01746749Q34206639-0AB984A0-1D0A-4108-A7B2-AEC00B1F3129Q34237245-58CDB7BD-6C55-49BA-B59D-93A71E679012Q34367414-5FC90B0F-B8BF-489F-8687-44A7162A6403Q34813547-A86BB6A3-A68A-4434-AEBA-5276C8F14736Q34976051-0AD89BBD-8D8F-474F-B97D-43A9268CB975Q35075535-E9E950FF-F8AE-473C-A884-08434A534D8BQ35104872-C18822DE-3C37-4873-87D6-28D70234C81AQ35138416-C7B6B7A6-7CD6-4B54-974E-7711C498C0C0Q35654500-D54D1849-C551-4BD0-B7B7-81B9AB385ABCQ36207151-21DB29DF-4CDF-4348-86EB-7026C52E9C22Q36355419-AFD16D01-CC62-4091-A5EB-85117FB54DADQ36898669-8CE52DFB-4491-433C-A8A4-F0D716FCBBC0Q37015889-44C0E19B-D72D-4541-84B9-760DF4893D2CQ37670529-C19CB8FF-5A06-4DA1-87AA-F18176CDA47AQ37734746-E2CEA652-4519-4C80-95E2-872D1DC0CA39Q37802876-1CF9BDC7-D66E-4D5A-B1B8-3941EEAE6312Q38086247-0CD35622-D9F6-4E26-9D34-4420E1656BC0Q38209922-FFD3ACAE-11C6-4D2F-9AC7-F1707106C4D5Q38382986-2BD795FF-56B0-4C72-828A-E2D7FBF74564Q38497438-42909665-73B4-4BD5-855A-22C682D13C30Q38756873-A4B83AFC-F51B-483E-AAB1-23608E001E45Q38896550-C58EF506-48F9-4C73-A616-5FF61B4B72AAQ39364535-90D839C1-A55B-4FE1-84CA-F7FE17CF3E13Q39887350-FC8B3BC7-69AB-4840-B299-BB3F3007B170Q40141872-EA998B4F-B4D2-407F-A4E1-8971266EA09BQ40578397-4E88F240-F794-453F-8F11-6D652AB27340Q40945601-58DFFA61-1DC7-44B0-B492-496123D00FDFQ42720701-7661EC34-364B-4AD4-AB17-EAB8AC0DC29CQ43495069-85EAB37E-9C28-44B2-AE22-0132EEBC8D9FQ45023688-F3334051-1EC2-4DAD-A7F3-85EF69B791EFQ45955692-D2ECE62D-EE60-4E17-A4A1-574D07308C0CQ46859509-588F0D01-BA2B-4071-9901-142330D7DBACQ48267704-97DF3D78-8AB8-4481-9975-FE1C251353E8Q49985633-86C17D4E-CD11-40B1-82EF-118A7E13E0E4
P2860
Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Identification of GP2, the maj ...... antibodies in Crohn's disease.
@ast
Identification of GP2, the maj ...... antibodies in Crohn's disease.
@en
type
label
Identification of GP2, the maj ...... antibodies in Crohn's disease.
@ast
Identification of GP2, the maj ...... antibodies in Crohn's disease.
@en
prefLabel
Identification of GP2, the maj ...... antibodies in Crohn's disease.
@ast
Identification of GP2, the maj ...... antibodies in Crohn's disease.
@en
P2093
P921
P356
P1433
P1476
Identification of GP2, the maj ...... antibodies in Crohn's disease.
@en
P2093
D Reinhold
G Hausdorf
L Martinez-Gamboa
P R Jungblut
P304
P356
10.1136/GUT.2008.162495
P407
P577
2009-06-22T00:00:00Z